2-((2-Chloro-6-fluorobenzyl)sulfanyl)-3-(3-pyridinyl)-4(3H)-quinazolinone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-((2-Chloro-6-fluorobenzyl)sulfanyl)-3-(3-pyridinyl)-4(3H)-quinazolinone
• 英文别名: 2-[(2-chloro-6-fluorophenyl)methylsulfanyl]-3-pyridin-3-ylquinazolin-4-one
• 化学式: C₂₀H₁₃ClFN₃OS
• 分子量: 397.9
• InChiKey: QOWRMFBXXDITMF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  70.9
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF
  申请人：Del Mar Pharmaceuticals

  公开号：EP2872161A2

  公开（公告）日：2015-05-20
• DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS
  申请人：Del Mar Pharmaceuticals

  公开号：EP2872161B1

  公开（公告）日：2020-12-16
• Small Molecules for Inhibition of Protein Kinases
  申请人：Desai Renee

  公开号：US20110275645A1

  公开（公告）日：2011-11-10

  The invention provides compounds that inhibit protein kinases, prodrugs of the compounds, intermediates and methods of synthesizing the compounds and/or prodrugs, pharmaceutical compositions including the compounds and/or prodrugs and methods of using the compounds and/or prodrugs in a variety of contexts, including, for example, in the treatment and/or prevention of various diseases that are responsive to protein kinase inhibition and/or that are mediated, at least in part, by inappropriate kinase activity.
• SMALL MOLECULE INHIBITORS OF PROTEIN KINASES
  申请人：Desai Ketan

  公开号：US20130058980A1

  公开（公告）日：2013-03-07

  Compounds that modulate, for example, that inhibit, syk kinase, and, optionally other kinases. The compounds can be used to treat a variety of disorders, including inflammatory disorders and autoimmune disorders.
• METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR
  申请人：Del Mar Pharmaceuticals (BC) Ltd.

  公开号：US20210251944A1

  公开（公告）日：2021-08-19

  Methods and compositions suitable for the treatment of malignancies in subjects with a germline deletion polymorphism that blocks the activity of thymidine kinase inhibitors in triggering apoptosis in tumor cells or in subjects having a mutation in or a dysregulation of the AHI-1 gene are disclosed. These methods employ an alkylating hexitol derivative such as dianhydrogalactitol, a derivative or analog of dianhydrogalactitol, diacetyldianhydrogalactitol, a derivative or analog of diacetyldianhydrogalactitol, dibromodulcitol, and a derivative or analog of dibromodulcitol. The compositions can include such alkylating hexitol derivatives. The methods can further include administration of a BH3 mimetic, and the compositions can further include a BH3 mimetic. In subjects having a dysregulation of the AHI-1 gene, the methods can further include the administration of an agent modulating the expression or activity of the AHI-1 gene or AHI-1 protein, and the compositions can further include such an agent.